NeurologyLive® Friday 5 — October 16, 2026

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

Don’t have time to read or watch a full video interview? Click here to check out our shorts!

Click the read more or watch now buttons for more details and information about each highlight.

1: Translating Alzheimer Disease Research From Bench to Bedside: Heather M. Snyder, PhD

In a recent interview, Heather M. Snyder, PhD, senior vice president of medical and scientific relations at the Alzheimer's Association, discussed key themes in Alzheimer disease research presented at AAIC 2026. [WATCH TIME: 8 minutes]

2: Where Sleep Medicine Is Heading After SLEEP 2026: Anita Shelgikar, MD, MHPE

In a recent interview, Anita Shelgikar, MD, MHPE, professor of neurology at the University of Michigan Medical School, discussed the themes that defined SLEEP 2026, and what they signal for clinical practice heading into 2027. [WATCH TIME: 5 minutes]

3: Individualizing Advanced Therapies in Parkinson Disease: Hubert Fernandez, MD

In a recent interview, Hubert Fernandez, MD, director of the Center for Neurological Restoration and head of Movement Disorders at Cleveland Clinic, discussed when to transition beyond oral medication and considerations for selecting device-aided therapies in PD. [WATCH TIME: 5 minutes]

4: NeuroVoices: Ali Habib, MD, on Cemdisiran and the Phase 3 NIMBLE Trial Data in Myasthenia Gravis

In a recent Q&A, Ali Habib, MD, professor of neurology and program director of Neuromuscular Medicine at UC Irvine, discusses phase 3 NIMBLE trial findings for cemdisiran in generalized myasthenia gravis, including its novel siRNA mechanism, efficacy, and hospitalization data.

5: The Road Ahead for Precision Medicine in Multiple Sclerosis

In this episode of our latest video series, Marisa McGinley, DO, presents her team’s model for predicting the risk of stopping MS therapy. Rebecca Cebull, CNP, and Robert Bermel, MD, explain why concrete, individualized risk data could change how patients and clinicians make treatment decisions.